The pathogenesis of parathyroid gland hyperplasia is poorly understood, and a better understanding is essential if there is to be improvement over the current strategies for prevention and treatment of secondary hyperparathyroidism. Here we investigate the specific role of Klotho expressed in the parathyroid glands (PTGs) in mediating parathyroid hormone (PTH) and serum calcium homeostasis, as well as the potential interaction between calciumsensing receptor (CaSR) and Klotho. We generated mouse strains with PTG-specific deletion of Klotho and CaSR and dual deletion of both genes. We show that ablating CaSR in the PTGs increases PTH synthesis, that Klotho has a pivotal role in suppressing PTH in the absence of CaSR, and that CaSR together with Klotho regulates PTH biosynthesis and PTG growth. We utilized the tdTomato gene in our mice to visualize and collect PTGs to reveal an inhibitory function of Klotho on PTG cell proliferation. Chronic hypocalcemia and ex vivo PTG culture demonstrated an independent role for Klotho in mediating PTH secretion. Moreover, we identify an interaction between PTG-expressed CaSR and Klotho. These findings reveal essential and interrelated functions for CaSR and Klotho during parathyroid hyperplasia.
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secondary hyperparathyroidism | FGF23 | chronic kidney disease | tdTomato | conditional knockout C hronic kidney disease (CKD) is a major, worldwide public health issue and has a high impact on mortality and morbidity. The overall CKD mortality has increased by 32% over the last decades (1) . In the United States, Medicare spending for patients with CKD ages 65 and older exceeded $55 billion in 2015, representing 20% of all Medicare spending in this age group, consuming substantial financial and social resources (2) . The most severe systemic problems are related to the mineral and hormonal imbalances that instigate secondary hyperparathyroidism (SHPT) accompanied by parathyroid gland (PTG) hyperplasia (3) . The metabolic imbalances and hyperplasia then reinforce each other as the disease progresses. SHPT in CKD is associated with renal osteodystrophy, extraskeletal calcification, impaired bone mineralization, and cardiovascular disease (4) . SHPT and the exacerbated mineral metabolism disturbances are the chief contributors to mortality in CKD patients (5) . The current treatment is to artificially balance one of the metabolic factors, use a combination of medications to balance multiple factors, or surgically remove the PTGs (6, 7) . A deeper understanding of how the PTGs initiate and maintain the hyperplastic state is of high clinical significance.
In healthy individuals, the PTG detects serum calcium levels via the calcium-sensing receptor (CaSR), a G protein-coupled receptor that modulates the secretion of parathyroid hormone (PTH) in response to low circulating levels of calcium to maintain homeostasis (8, 9) . PTH targets the kidneys to (i) stimulate calcium reabsorption and (ii) increase the production of active vitamin D, which in turn induces intestinal calcium absorption (10) . Fibroblast growth factor 23 (FGF23) is secreted by bone in response to higher serum 1,25-dihydroxyvitamin D [1, 25(OH) 2 D 3 ] and phosphate levels and as a consequence of the changes in calcium metabolism initiated by PTH (11) . PTH plays an important role in promoting FGF23 transcription and serum FGF23 concentration. Previous studies have elucidated that PTH directly induces FGF23 production in a vitamin D-independent manner (12) (13) (14) . PTH expression and production are suppressed as serum levels of calcium, vitamin D, and FGF23 rise in response to PTH's actions, thus providing a negative control mechanism to maintain proper balance (15) (16) (17) . As CKD develops and progresses, however, this regulatory network breaks down and serum PTH levels increase despite significant elevated serum FGF23 levels (15) . The mechanism underlying this resistance to regulatory control is not Significance Secondary hyperparathyroidism (SHPT) is a severe consequence of chronic kidney disease. A better understanding of the mechanisms controlling the progression of SHPT and the regulation of parathyroid hormone (PTH) production is clinically relevant. Utilizing parathyroid gland (PTG)-specific knockout mouse models, we demonstrated calcium-sensing receptor (CaSR) and Klotho together regulate PTH synthesis and PTG growth, and that Klotho contributes to PTH suppression in the absence of CaSR. Klotho exerts an independent function in mediating PTH secretion under chronic hypocalcemia and in suppressing PTG cell proliferation. Moreover, the results revealed a previously unidentified interaction between PTG-expressed CaSR and Klotho. These findings highlight the essential and interrelated roles for CaSR and Klotho to prevent parathyroid hyperplasia, suggesting potential treatment strategies to control PTH synthesis and hyperparathyroidism.
fully understood, although some key issues have been identified (18) . These include the drop in vitamin D levels due to the high FGF23 and a reduction in the expression of FGF23's required cofactor, Klotho, and its receptor, fibroblast growth factor receptor 1 (FGFR1), in the PTGs, reducing the ability of FGF23 to efficiently control the PTG function (18, 19) .
Type I membrane-bound alpha-Klotho (Klotho, KL) is a transmembrane protein that has been found in mice, rats, and humans predominantly in the renal distal convoluted tubular cells and to a lesser extent in proximal convoluted tubular epithelial cells and the PTGs (18, 20, 21) . It is also expressed in various organ systems, including arterial, epithelial, reproductive, and neuronal tissues (22) . The principal role of Klotho is to form the specific receptor complex with FGFR1 that is required for FGF23 signaling (23) (24) (25) . Activation of the FGFR1-Klotho complex by FGF23 in the kidney regulates phosphate homeostasis by affecting the expression of sodium-phosphate cotransporters, Napi2a and Napi2c, in the proximal tubules. It also inhibits 1,25(OH) 2 D 3 synthesis by altering the vitamin D-metabolizing enzymes CYP27b1 and CYP24a1 (26) (27) (28) (29) . Noteworthy, Klotho is also highly expressed in the PTGs, but a link between Klotho and PTH in the regulation of serum calcium homeostasis has not yet been investigated. FGF23-Klotho signaling has been shown to inhibit PTH mRNA transcription and hormone secretion in vitro (30) and to negatively regulate PTH secretion in vivo (15) . It has also been shown that the calcineurin-mediated FGF23 signaling pathway in PTGs mediates suppression of PTH (31) . Contrary to these studies, Fgf23
−/− mice overexpressing human recombinant FGF23 under the control of the 2.3-kb collagen 1 promoter exhibited high serum PTH despite unchanged serum calcium and 1,25(OH) 2 D 3 levels, and despite hypophosphatemia (32) . It has been suggested that FGF23 is a long-term inducer of PTH during CKD (33) . Klotho activity has been implicated as fundamental for the stimulation of PTH secretion in hypocalcemia conditions by recruiting Na (34) , although the underlying mechanism has been challenged (35) .
In this study, we sought to determine the tissue-specific role of Klotho in PTGs in controlling PTH and serum calcium homeostasis and to explore a potential interaction between Klotho and CaSR in proper PTH regulation. We therefore generated mouse strains with a parathyroid-specific deletion of Klotho or CaSR and a parathyroid-specific dual deletion of both genes. The results of our study reveal an independent function of PTG Klotho to regulate PTH production and cell proliferation, as well as a possible interaction between Klotho and CaSR.
Materials and Methods
Animals. Mice with a PTG-specific deletion of Klotho, CaSR, or both together were generated using the Cre-LoxP recombination system. The derivation of the PTHcre;KL fl/fl mice was previously described (31 Coimmunoprecipitation Assay. HEK293 cells were cultured in DMEM with 10% FBS, 4.5 g/L D-glucose, 584 mg/L L-glutamine, 110 mg/L sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen). The pRK5-GFPCaSR plasmid was kindly provided by Jeremy M. Henley, University of Bristol, Bristol, UK (40) . The pCS-mKLcFT plasmid was obtained from Makoto Kuro-o, Jichi Medical University, Shimotsuke, Japan (41) . Cells grown in 100-mm culture dishes were transfected with 4 μg of cDNA using PolyJet In Vitro DNA Transfection Reagent (SignaGen Laboratories) according to the manufacturer's protocol. Cells were homogenized with radioimmunoprecipitation assay buffer (Alfa Aesar) containing phosphatase and protease inhibitor mixture tablets (Roche) and centrifuged at 14,000 × g. The supernatant was then transferred to a fresh tube. Protein concentration was measured by BCA protein assay (Pierce). Immunoprecipitation was performed using Protein A/G PLUS-Agarose Immunoprecipitation Reagent (sc-2003; Santa Cruz) according to the manufacturer's protocol. Protein samples were heated with NuPAGE LDS Sample buffer and NuPAGE Reducing Agent (Life Technologies) at 70°C for 10 min and then subjected to NuPAGE 4-12% Bis-Tris SDS/PAGE using precast gels (Invitrogen) and NuPAGE Mes SDS running buffer (Life Technologies). The separated proteins in the gel were electrophoretically transferred to Hybond-P polyvinylidenedifluoride transfer membranes. After incubation in blocking solution for 1 h, the membranes were further treated with a rat anti-human Klotho monoclonal antibody (1:1,000, KM2076; Cosmo Bio) or rabbit anti-GFP antibody (1:1,000; Invitrogen). Horseradish peroxidase-conjugated anti-rat or rabbit IgG was used as the secondary antibody (Jackson ImmunoResearch Laboratories), and signal was detected by Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare).
Statistics. GraphPad Prism 6.0 (GraphPad Software Inc.) was used for statistical analysis. Comparisons between groups were evaluated by unpaired two-tailed Student's t test between two groups or by one-way ANOVA followed by Tukey's test for multiple comparisons. Two-way ANOVA and Bonferroni posttests were used to evaluate individual samples between control diet and low-Ca 2+ diet. All values are expressed as mean ± SEM. P values <0.05 were considered significant for all analyses.
Extended methods and information about genotyping, serum and urine measurements, PTG isolation, ex vivo PTG culture, RNA isolation, and qRT-PCR analyses, skeletal preparations and bone histology, and Western blot are described in SI Materials and Methods. Mice. Mice with PTG-specific deletion of Klotho or CaSR, and mice with specific deletion of both, were generated using CreLoxP recombination. Immunostaining and qRT-PCR using PTG RNA confirmed efficient deletion of Klotho and CaSR in the PTG tissue with the according genotype at protein and mRNA levels, respectively (Fig. S1 ). These mice were born at the expected Mendelian ratio. PTHCre;KL fl/fl mice were viable and appeared macroscopically normal in size and weight. However, ;CaSR fl/fl mice were severely growth-retarded (Fig. 1A) . These mice had reduced body weight compared with control littermates (KL Fig. 1 D-H (Fig. 1 D-H S2 A and B) . Moreover, these mice had significantly increased renal Cyp27b1 gene expression (Fig. S2C) S2 D-F) . Radiographs of hind limbs showed no significant changes in bone due to Klotho deletion, while CaSR deletion in PTGs led to markedly increased radiolucency in metaphysis and diaphysis (Fig. S3A) 2 A and B) . We next examined the histology of the PTGs at P10. We generated paraffin sections and used H&E staining to confirm the size difference (Fig. 2C) . The results suggested that no significant structural difference could be detected between PTHCre;KL ;CaSR fl/fl PTGs appeared to be larger. Also, the glands contained more eosinophilic areas with nodular formations. The morphological structure is more severe and disrupted in double-mutant mice (Fig. 2C) . A proliferation analysis revealed a significant increase in the percentage of Ki67-positive cells in ;CaSR fl/fl PTGs compared with controls. This confirms that an increase in proliferation contributed to the enlargement of the glands (Fig. 2 D and E) .
Results

Generation of
Both Klotho and CaSR Control the Expression Pattern of PTH. We performed immunofluorescence double staining for PTH and CaSR to investigate the PTH expression pattern in the presence and absence of CaSR. Confocal images of double-stained sections showed a normal PTH distribution, coordinated with the CaSR expression pattern in PTHcre;KL fl/fl mice ( Fig. 3 A and B) . PTGs, many nodules were visible at CaSR-negative areas that were also highly positive for PTH, indicating that CaSR-deficient cells are contributing to higher PTH synthesis ( Fig. 3 A and B) . Total RNA from PTGs was extracted at P10 for qRT-PCR analysis; however, no changes were observed in Pth mRNA expression, despite the markedly elevated serum PTH levels in PTHcre; CaSR fl/fl and PTHcre;KL fl/fl ;CaSR fl/fl mice (Fig. 3C) . Surprisingly, we observed areas of altered tissue structure in some extremely hyperplastic PTGs of PTHcre;KL fl/fl ;CaSR fl/fl mice that failed to express PTH protein (Fig. S4 A and B) . To investigate whether this could be due to cell death, we performed TUNEL staining. The results suggested that ablation of CaSR leads to increased parathyroid cell apoptosis, which is even more pronounced in the PTHcre;KL fl/fl ;CaSR fl/fl glands ( Fig. S4 C and D) . We next investigated a few consequences on gene transcription upon deletion of Klotho/CaSR from PTGs. The results demonstrated that expression of Fgfr1, Egr1, and 1α(OH)ase were slightly reduced in PTGs of Klotho-deficient mice. Furthermore, CaSR deletion resulted in increased 24(OH)ase expression levels, which exhibited comparatively lower expression in Klotho-ablated glands. Moreover, mutant mice lacking Klotho, CaSR, or both showed reduced expression of Vdr (Fig. S5 A-E) . We next explored the MAP kinase cascade using immunofluorescence staining. As shown in Fig. S5 F and G 2+ and Pi levels were significantly reduced in all genotypes after being on the low-Ca 2+ diet (Fig. 4 A and B) . As expected, the low-Ca 2+ diet significantly increased serum PTH levels by around sevenfold in PTHCre;Tm fl/+ mice compared with those on a control diet (Fig. 4C) ;CaSR fl/+ mice (Fig. 4C ). This is consistent with the previous observation that dual deletion of Klotho and CaSR in the PTGs at P10 resulted in excess secretion of PTH and confirms that ablation of both factors results in abnormal production of PTH.
PTH immunostaining suggested that the pattern of PTHsecreting cells appeared normal in PTHCre;Tm fl/+ and PTHCre; Tm PTH protein expression under control or low-Ca 2+ diet conditions (Fig. 4D) (Fig. 5 A and B) . A lowCa 2+ diet induced PTG hyperplasia in all genotypes, but a more severe increase occurred in the absence of Klotho (Fig. 5 A and  B) . Histological analyses of H&E-stained paraffin sections of PTGs showed that under a control diet PTG tissue from PTHCre;Tm fl/+ ;KL fl/fl , PTHCre;Tm fl/+ ;CaSR fl/+ , and PTHCre; ;KL fl/fl ;CaSR fl/+ mice appeared to be more eosinophilic compared with that of control glands (Fig. 5C ). There was a significant increase in the PTG volume in all groups in response to hypocalcemia.
Ki67 immunostaining showed that glands with Klotho or Klotho/CaSR deletion exhibit increased cell proliferation under control diet conditions compared with control glands (Fig. 6) . Furthermore, chronic hypocalcemia induced by low-Ca 2+ diet resulted in a significant up-regulation of Ki67-positive cells only in Klotho-ablated PTGs, indicating that an increase in cell proliferation contributed to the observed PTG hyperplasia in the absence of Klotho (Fig. 6) . TUNEL staining showed that cell apoptosis was not affected by Klotho or partial CaSR deletion or by diet conditions. These results suggest that Klotho and CaSR have an important role in PTG growth by regulating cell proliferation. Deletion of either factor leads to PTG hyperplasia (Fig. S6) .
Interaction of Klotho and CaSR in PTGs. We isolated PTGs using tdTomato fluorescence to eliminate any contamination by surrounding thyroid tissue. qRT-PCR analyses and immunostaining showed that deletion of Klotho leads to a tendency of lower CaSR expression on either protein or mRNA levels at P10 (Fig.  7 A and B) . Interestingly, however, Klotho mRNA expression levels were significantly decreased in CaSR-deleted PTGs (Fig.  7D) , which was also confirmed at the protein level by immunostaining (Fig. 7C) . This finding suggests a potential interaction between CaSR and Klotho. Dual deletion of Klotho and CaSR resulted in merely undetectable Klotho expression (Fig. 7C) ) conditions. qRT-PCR results showed that high Ca 2+ had no effect on Klotho gene expression in control PTGs (Fig. 7G) , suggesting that the deletion of the CaSR itself is responsible for the reduced Klotho expression in PTGs, and that this down-regulation is independent of serum calcium PTGs compared with controls (Fig. 7E) . Concurrently, CaSR expression was also found to be significantly reduced in Klothodeficient PTGs at 6 wk (Fig. 7F) . . This was correlated with serum Ca 2+ levels, suggesting Klotho and CaSR together control PTH synthesis and deletion of only one allele of either protein resulted in more severe phenotype (Fig. S7 A and B) .
Moreover, we have compared the serum PTH and Ca 2+ values of control animals and mice with Klotho ablation alone, with or without heterozygous CaSR deletion, at 6-wk of age (Fig. S7 C  and D) . The result was similar to what we observed at P10: Serum PTH levels exhibited a tendency to increase among these animals, confirming the synergistic effect of Klotho and CaSR in controlling PTH synthesis.
We further investigated the possibility of an interaction between Klotho and CaSR using coimmunoprecipitation assays. HEK293 cells were transfected with Klotho alone, CaSR alone, or Klotho+CaSR. Klotho and CaSR were then precipitated by Klotho (or Flag) or CaSR (or GFP) antibodies, respectively. The results demonstrated that Klotho coimmunoprecipitates with CaSR (Fig. 7H) , suggesting a physical interaction between Klotho and CaSR.
Discussion
In the current study we generated mice with a PTG-specific deletion of Klotho alone or together with CaSR to better understand their functional mechanisms and determine any potential interactions. Deleting Klotho in PTGs did not affect key serum and urinary parameters. PTHCre;CaSR fl/fl mice displayed hypercalcemia, hypophosphatemia, and significantly elevated serum PTH, iFGF23, and 1,25(OH) 2 D 3 levels, resembling the phenotype of CaSR −/− mice (42) . Combined deletion of Klotho and CaSR (PTHCre;KL fl/fl ;CaSR fl/fl ) resulted in significantly higher serum PTH, iFGF23, and 1,25(OH) 2 D 3 levels compared with PTHCre;CaSR fl/fl mice. There are several ways to interpret these data. First, Klotho deletion could impede the FGF23 feedback loop that suppresses PTH in PTGs. The moderately or severely elevated serum PTH observed in CaSR-deletion versus CaSR+Klotho-deletion mice might depend on Klotho genedosage effects. Second, PTG hyperplasia developed in both mutants, but mice with dual deletion exhibited the largest effect. Pth mRNA levels were comparable between these mice, but the greater hyperplasia in PTHCre;KL fl/fl ;CaSR fl/fl mice might lead to an increased parathyroid cell number and thus enhanced PTH synthesis and higher serum PTH levels. Third, PTHCre;KL fl/fl ; CaSR fl/fl PTGs exhibited a more severe alteration of PTG morphology, accompanied by increased PTG nodule formations, which might also lead to higher PTH secretion. These results collectively indicate that Klotho is a negative regulator of PTH synthesis in the absence of CaSR. Serum PTH levels remained constant in PTHcre;Klotho fl/fl mice, suggesting that the CaSR has a dominant function in modulating PTH production. Klotho may serve as a supplementary factor in response to changes in serum calcium, especially when CaSR function is diminished. Renal Klotho is known to enhance renal Ca 2+ absorption by stabilizing the transient receptor potential vanilloid 5 acting as a β-glucuronidase (43) and is an important factor in the prevention of renal Ca 2+ loss (44) . We investigated the action of parathyroid Klotho in the proper response to serum calcium. A previous study using single injections of EGTA or calcium gluconate to change serum calcium levels demonstrated that PTG Klotho is not essential for PTH secretion in response to acute alterations in serum calcium (31) . However, we challenged mice with a Ca ;CaSR fl/+ mice compared with control mice under low-Ca 2+ condition. This result is in accord with a previous report that showed homozygous Klotho knockout mice did not secrete as much PTH as control mice under hypocalcemia (34) . Interestingly, ex vivo experiments showed that Klotho-deficient PTGs had more pronounced secretion of PTH under low-Ca 2+ condition void of the influence by other circulating components, suggesting an independent role for Klotho in suppressing PTH secretion. Therefore, we speculate that the inconsistency of in vivo and ex vivo PTH production might be due to some systemic inhibitory factors preventing PTH secretion in PTHcre;Tm fl/+ ;KL fl/fl mice under chronic hypocalcemia. Thus, additional investigations are required to determine the in vivo regulatory network on PTH secretion.
Accumulating evidence suggests that a chronic increase in PTH production, characteristic of primary or secondary hyperparathyroidism, is accompanied by an increase in PTG size (45) (46) (47) . Determination of gland size is particularly difficult (48), so we generated mice with a Tomato reporter gene in which red fluorescent protein is selectively expressed in parathyroid cells. Mice with ablation of PTG-CaSR at P10 or heterozygous PTGspecific deletion of CaSR at 6 wk of age had significantly enlarged glands compared with controls, confirming the pivotal function of CaSR in determining PTG growth. Klotho expression is reduced as the PTG tissue becomes hyperplastic (19) , as seen in patients with hyperphosphatemic familial tumoral calcinosis (49) . It was unclear whether Klotho was a contributing factor to hyperplasia, a consequence of hyperplasia, or some combination of the two. Our results revealed that Klotho has a more prominent role in the development of hyperplasia and/or SHPT. PTGspecific Klotho deletion only leads to a trend of increasing PTG size at P10. However, the combined deletion of Klotho and CaSR caused significant PTG hyperplasia. The additional gland enlargement in PTHCre;KL fl/fl ;CaSR fl/fl mice compared with PTHCre;CaSR fl/fl mice indicates a role of Klotho in preventing the development of hyperplasia in the absence of a functional CaSR. Interestingly, cell proliferation appears to be more important than cell apoptosis to the increase in PTG volume. It is important to note that the critical role of Klotho in preventing PTG hyperplasia is demonstrated in our prolonged observation that mice with PTG-specific Klotho ablation at 6 wk of age exhibited a substantial increase in PTG size compared with control and PTHcre;Tm fl/+ ;CaSR fl/+ mice on a control diet. These results emphasize Klotho's function in suppressing PTG hyperplasia.
An increase in PTG volume, reportedly due to enhanced hypertrophy, has been observed in hypocalcemic animals with normal renal function on a calcium-deficient diet (50) . Another finding showed that parathyroid cell hyperplasia largely prevailed over hypertrophy in rats on a low-calcium diet (51) . Analyses of human hyperparathyroidism samples found evidence of apoptosis (52, 53) . The percentage of PTG apoptotic cells in controls was ∼0.15% in P10 mice and less than 0.1% in 6-wk-old mice, but PTG-specific ablation of CaSR led to significantly increased cell apoptosis. This was more evident in dual deletion of CaSR and Klotho at P10. Nevertheless, cell proliferation prevailed over apoptosis in these mice. Enhanced cell proliferation was observed under chronic hypocalcemia, and cell apoptosis was not altered in 6-wk-old mice. Thus, the higher rate of cell proliferation over apoptosis results in the enlargement of PTG volume, similar to the observations in hyperplastic PTG tissue of uremic patients (53, 54) . We also observed that in some extremely hyperplastic PTGs from PTHCre;KL fl/fl ;CaSR fl/fl mice, PTH was not expressed in some areas of altered structure, probably due to increased apoptosis. We found that an enlargement of PTG size was detected in all groups under hypocalcemia and revealed that hypocalcemia significantly enhanced cell proliferation. This was more pronounced in mice deficient in PTG Klotho, confirming that reduced Klotho expression could direct PTG hyperplasia by mediating cell proliferation.
Previous studies showed Klotho and CaSR expression were significantly decreased in PTGs of PHTP, SHPT patients, patients after kidney transplantation, and those with end-stage renal disease (55) (56) (57) . We could demonstrate a binding interaction between Klotho and CaSR that might play a synergistic effect in controlling PTH synthesis and glandular hyperplasia. Several lines of experimental evidence support this tenet. PTG-specific deletion of CaSR, for example, leads to significantly reduced Klotho transcript and protein levels at P10. Moreover, even heterozygous PTG CaSR ablation resulted in markedly reduced Klotho expression. Ex vivo PTG culture revealed that Klotho expression was not affected by changes in calcium levels, indicating that the observed reduction in Klotho expression in vivo was largely due to CaSR ablation. On the contrary, PTG Klotho deletion significantly reduced CaSR expression at 6 wk of age. A trend toward decreased CaSR expression was already noted at P10 in PTHCre;KL fl/fl PTGs. Moreover, we were able to demonstrate that Klotho and CaSR bind to each other using coimmunoprecipitation. Technical issues related to the small size of the glands limited further investigations of in vivo coimmunoprecipitation experiments. However, we were able to show protein colocalization of CaSR and Klotho by immunostaining (Fig.  S7E) , consistent with these two proteins acting together to mediate PTH synthesis and PTG growth.
In summary, we demonstrated that the specific deletion of CaSR in the PTGs leads to elevated serum PTH and PTG hyperplasia, and that additional deletion of Klotho in PTGs exacerbated this condition. This suggests a pivotal function for Klotho in suppressing PTH biosynthesis and PTG growth in the absence of CaSR. Moreover, we were able to demonstrate that Klotho exhibits an independent role to modulate PTH production under chronic hypocalcemia and acts as an inhibitory factor on parathyroid cell proliferation, indicating a physiological function for Klotho in modulating the hyperplasia or SHPT. Most importantly, our findings propose a physical interaction between Klotho and CaSR. Nevertheless, the molecular mechanism by which Klotho and CaSR regulate each other requires further investigation. The results suggest that up-regulation or activation of Klotho could provide a potential treatment to control circulating PTH and hyperparathyroidism.
